BR112014004828B8 - Métodos para preparação de composições compreendendo anticorpos ou proteínas concentradas por ultrafiltração - Google Patents

Métodos para preparação de composições compreendendo anticorpos ou proteínas concentradas por ultrafiltração

Info

Publication number
BR112014004828B8
BR112014004828B8 BR112014004828A BR112014004828A BR112014004828B8 BR 112014004828 B8 BR112014004828 B8 BR 112014004828B8 BR 112014004828 A BR112014004828 A BR 112014004828A BR 112014004828 A BR112014004828 A BR 112014004828A BR 112014004828 B8 BR112014004828 B8 BR 112014004828B8
Authority
BR
Brazil
Prior art keywords
ultrafiltration
antibodies
methods
preparing compositions
proteins concentrated
Prior art date
Application number
BR112014004828A
Other languages
English (en)
Other versions
BR112014004828A2 (pt
BR112014004828B1 (pt
Inventor
Hidenari Yamada
Jean Bender
Kelby Lau
Masayoshi Oh-Eda
Rumiko Wakayama
Saeko Tanaka
Tomonori Isoda
Original Assignee
Chugai Pharmaceutical Co Ltd
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd, Genentech Inc filed Critical Chugai Pharmaceutical Co Ltd
Publication of BR112014004828A2 publication Critical patent/BR112014004828A2/pt
Publication of BR112014004828B1 publication Critical patent/BR112014004828B1/pt
Publication of BR112014004828B8 publication Critical patent/BR112014004828B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/34Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D61/00Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14Ultrafiltration; Microfiltration
    • B01D61/145Ultrafiltration
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2311/00Details relating to membrane separation process operations and control
    • B01D2311/14Pressure control
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2311/00Details relating to membrane separation process operations and control
    • B01D2311/16Flow or flux control
    • B01D2311/165Cross-flow velocity control
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2315/00Details relating to the membrane module operation
    • B01D2315/14Batch-systems
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2321/00Details relating to membrane cleaning, regeneration, sterilization or to the prevention of fouling
    • B01D2321/02Forward flushing
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D61/00Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14Ultrafiltration; Microfiltration
    • B01D61/22Controlling or regulating

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

composições líquidas compreendendo anticorpos altamente concentrados por ultrafiltração e seu método de preparação. a presente invenção se referee a um método para preparação de uma composição compreendendo anticorpos altamente concentrados pela ultrafiltração em modo de concentração em batelada tendo uma primeira taxa de alimentação constante e uma segunda taxa de alimentação controlada. a invenção se refere, ainda, a composições obtidas pelo referido método.
BR112014004828A 2011-09-01 2012-08-31 Métodos para preparação de composições compreendendo anticorpos ou proteínas concentradas por ultrafiltração BR112014004828B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161530158P 2011-09-01 2011-09-01
US61/530,158 2011-09-01
PCT/JP2012/005536 WO2013031237A1 (en) 2011-09-01 2012-08-31 Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration

Publications (3)

Publication Number Publication Date
BR112014004828A2 BR112014004828A2 (pt) 2017-04-04
BR112014004828B1 BR112014004828B1 (pt) 2021-03-09
BR112014004828B8 true BR112014004828B8 (pt) 2022-03-29

Family

ID=46982845

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014004828A BR112014004828B8 (pt) 2011-09-01 2012-08-31 Métodos para preparação de composições compreendendo anticorpos ou proteínas concentradas por ultrafiltração

Country Status (15)

Country Link
US (3) US9630988B2 (pt)
EP (2) EP3235557A1 (pt)
JP (2) JP6363017B2 (pt)
KR (1) KR101993488B1 (pt)
CN (1) CN103889555B (pt)
AU (2) AU2012303372A1 (pt)
BR (1) BR112014004828B8 (pt)
CA (1) CA2847302C (pt)
IL (1) IL231128B (pt)
MX (1) MX359235B (pt)
MY (1) MY182178A (pt)
RU (1) RU2638859C9 (pt)
SG (1) SG11201400260TA (pt)
WO (1) WO2013031237A1 (pt)
ZA (1) ZA201401184B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2312184T3 (es) 1997-03-21 2009-02-16 Chugai Seiyaku Kabushiki Kaisha Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas.
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
JP5711751B2 (ja) 2009-10-26 2015-05-07 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft グリコシル化された免疫グロブリンの調製方法
MX2013005024A (es) 2010-11-08 2013-11-21 Chugai Pharmaceutical Co Ltd Anticuerpo anti-il-6 receptor administrado subcutaneamente.
EP2739157B1 (en) * 2011-08-03 2017-10-04 Prolacta Bioscience, Inc. Microfiltration of human milk to reduce bacterial contamination
CA2913687C (en) 2013-07-04 2022-12-13 F. Hoffmann-La Roche Ag Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples
WO2016067177A1 (en) 2014-10-27 2016-05-06 Tmci Padovan S.P.A. Improved filtration plant and relative method
CN104673666A (zh) * 2015-03-10 2015-06-03 华东理工大学 一种微型切向流过滤模拟装置
GB201600287D0 (en) * 2016-01-07 2016-02-24 Fujifilm Diosynth Biotechnologies Uk Ltd Process
WO2018053253A1 (en) * 2016-09-15 2018-03-22 Evoqua Water Technologies Llc Method and system for treating ultrapure water
JP6399723B1 (ja) * 2018-02-21 2018-10-03 株式会社グロータック 自転車用変速操作装置
WO2020019080A1 (en) 2018-07-27 2020-01-30 Arc Medical Devices Inc. Highly purified and/or modified fucan compositions for the treatment of fibrous adhesions
US20210171573A1 (en) * 2018-08-14 2021-06-10 Bristol-Myers Squibb Company Improved protein recovery
DE102019101745A1 (de) * 2019-01-24 2020-07-30 Putsch Gmbh & Co. Kg Verfahren zum Betrieb einer Membranfilteranlage
MX2021000866A (es) * 2019-03-05 2021-06-15 Arc Medical Devices Inc Sistemas y metodos para la filtracion de flujo tangencial de composiciones viscosas.
CN111018968B (zh) * 2019-12-16 2021-07-27 兴盟生物医药(苏州)有限公司 一种通过超滤浓缩制备高浓度抗体制剂的方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6443305A (en) * 1987-08-10 1989-02-15 Fuji Photo Film Co Ltd Cross flow type filtration process
KR910002501A (ko) * 1989-07-14 1991-02-25 리차드 지. 워터맨 동방성 또는 이방성 미소다공성 신디오택틱 폴리스티렌 막 및 이의 제조방법
JPH0380921A (ja) * 1989-08-24 1991-04-05 Shinko Pantec Co Ltd 膜濾過装置の運転方法
JPH0778025B2 (ja) * 1990-03-20 1995-08-23 日本赤十字社 免疫グロブリンgの製造方法
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
JP3091885B2 (ja) 1991-07-05 2000-09-25 株式会社日立製作所 高温型二次電池及び電池モジュール
AU744146B2 (en) 1996-09-26 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Antibody against human parathormone related peptides
UA76934C2 (en) 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
AU735695B2 (en) * 1996-10-10 2001-07-12 Neose Technologies, Inc. Carbohydrate purification using ultrafiltration, reverse osmosis and nanofiltration
CH692479A5 (de) * 1997-07-08 2002-07-15 Bucher Guyer Ag Querstrom-Filtrationsanlage sowie Verfahren zum Betrieb einer solchen Anlage.
US6096872A (en) * 1997-10-14 2000-08-01 Ortho Diagnostic Systems, Inc. Viral clearance process
JP3998419B2 (ja) 1998-04-03 2007-10-24 中外製薬株式会社 ヒト組織因子(tf)に対するヒト型化抗体およびヒト型化抗体の作製方法
DE19827473C1 (de) * 1998-06-19 1999-08-26 Sartorius Gmbh Verbesserte Crossflow-Filterkassetten
TWI242043B (en) 2000-03-10 2005-10-21 Chugai Pharmaceutical Co Ltd Polypeptide inducing apoptosis
US6350382B1 (en) * 2000-06-23 2002-02-26 Scilog, Inc. Enhancing filtration yields in tangential flow filtration
ES2332402T5 (es) 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
AU2002210917B2 (en) 2000-10-20 2006-05-18 Chugai Seiyaku Kabushiki Kaisha Degraded TPO agonist antibody
WO2002092802A1 (en) * 2001-05-14 2002-11-21 Diversa Corporation Novel methods of enzyme purification
EP1551875A4 (en) * 2002-06-21 2006-06-28 Biogen Idec Inc TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
JP2006515227A (ja) 2003-02-24 2006-05-25 ジーティーシー バイオセラピューティックス インコーポレイテッド 十字流濾過の方法およびそのための装置
JP5452835B2 (ja) 2003-07-15 2014-03-26 中外製薬株式会社 形質転換細胞によるIgMの産生とその定量方法
WO2005077208A1 (de) 2004-02-18 2005-08-25 Bucher Guyer Ag Verfahren zur diafiltration eines produktes und vorrichtung zur durchführung des verfahrens
US7410587B2 (en) 2004-08-03 2008-08-12 Scilog, Inc. Liquid handling for filtration and preparative chromatography
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
US8741600B2 (en) 2007-06-19 2014-06-03 Asahi Kasei Kabushiki Kaisha Method for separation of immunoglobulin monomers
JP5099930B2 (ja) * 2007-06-19 2012-12-19 旭化成株式会社 免疫グロブリン1量体の分離方法
ES2834741T3 (es) 2007-12-05 2021-06-18 Chugai Pharmaceutical Co Ltd Anticuerpo anti-NR10 y uso del mismo
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
NZ589297A (en) * 2008-05-15 2011-12-22 Health L P W Process for producing milk fractions rich in secretory immunoglobulins
JP2010047527A (ja) * 2008-08-22 2010-03-04 Asahi Kasei Corp 免疫グロブリン1量体の分離方法
US9586180B2 (en) * 2009-03-24 2017-03-07 Wyeth Llc Membrane evaporation for generating highly concentrated protein therapeutics
JP2010248092A (ja) * 2009-04-13 2010-11-04 Asahi Kasei Corp 免疫グロブリン1量体の分離方法
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos

Also Published As

Publication number Publication date
US20200172569A1 (en) 2020-06-04
US20170204135A1 (en) 2017-07-20
WO2013031237A1 (en) 2013-03-07
AU2012303372A1 (en) 2014-02-20
IL231128A0 (en) 2014-03-31
ZA201401184B (en) 2014-12-23
US9630988B2 (en) 2017-04-25
NZ621902A (en) 2016-06-24
RU2638859C9 (ru) 2018-01-31
JP6363751B2 (ja) 2018-07-25
KR101993488B1 (ko) 2019-06-26
AU2017204395A1 (en) 2017-07-20
CN103889555A (zh) 2014-06-25
MX359235B (es) 2018-09-20
MX2014002253A (es) 2014-04-30
CN103889555B (zh) 2018-10-26
SG11201400260TA (en) 2014-03-28
CA2847302C (en) 2021-02-16
MY182178A (en) 2021-01-18
AU2017204395B2 (en) 2018-11-08
JP2014526371A (ja) 2014-10-06
EP2750784A1 (en) 2014-07-09
JP2017131886A (ja) 2017-08-03
US20150037319A1 (en) 2015-02-05
BR112014004828A2 (pt) 2017-04-04
IL231128B (en) 2019-03-31
JP6363017B2 (ja) 2018-07-25
US10590164B2 (en) 2020-03-17
KR20140078642A (ko) 2014-06-25
RU2638859C2 (ru) 2017-12-18
CA2847302A1 (en) 2013-03-07
EP3235557A1 (en) 2017-10-25
BR112014004828B1 (pt) 2021-03-09
RU2014112230A (ru) 2015-10-10

Similar Documents

Publication Publication Date Title
BR112014004828B8 (pt) Métodos para preparação de composições compreendendo anticorpos ou proteínas concentradas por ultrafiltração
BR112013012617A2 (pt) uso de glicosidase na preparação de um produto do leite
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
BR112015019879A2 (pt) Composições de espécies de variantes moduladas de lisina e métodos para produção e uso das mesmas
EA201391298A1 (ru) Неводные концентрированные суспензионные композиции с пониженной вязкостью на основе антител
EA201491644A1 (ru) Фармацевтические композиции
FI20115156A0 (fi) Maitopohjainen tuote ja menetelmä sen valmistamiseksi
EA201690651A1 (ru) Содержащие cmp высокобелковые композиции денатурированного сывороточного белка, содержащие их продукты и их применения
WO2014004436A3 (en) Crystalline anti-human il-23 antibodies
AR089178A1 (es) Anticuerpos anti-il-36r
MX2018003298A (es) Metodo para preparar una formulacion de proteinas terapeuticas y formulacion de anticuerpos producida por tal metodo.
MY170720A (en) Antibody formulations
AR100343A1 (es) Composición líquida para confitura congelada, método de producción y proceso de preparación
BR112016004510A2 (pt) composições bioativas deriváveis de concentrados de plaquetas e métodos para preparar e usar as mesmas
BR112016002401A2 (pt) métodos para reduzir as taxas de exacerbação de asma usando benralizumab
EA201391488A1 (ru) Композиции со сниженной вязкостью
EA201490024A1 (ru) Наполненные силиконовые композиции, их получение и применение
WO2013086448A3 (en) IgG2 DISULFIDE ISOFORM SEPARATION
PH12015500061A1 (en) Method for preparing substituted triazolopyridines
BR112019003709A2 (pt) nanopartículas de silício multifuncionalizadas, usos de nanopartículas de silício multifuncionalizadas, composição e métodos para medir um analito por um método in vitro
EA201391595A1 (ru) Новый металлопротеин, способ его получения и профилактический или терапевтический агент при заболеваниях роговицы или конъюнктивы, содержащий указанный металлопротеин
MY169137A (en) Method for producing ?-gamma-glutamyl-valyl-glycine crystal
JP2015517506A5 (pt)
RU2013111568A (ru) Композиция для получения молочно-белкового биококтейля
UA86850U (ru) Состав масляной пасты, обогащенной сывороточными белками

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/08/2012, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2618 DE 09/03/2021 QUANTO AO TITULO.